Bioxytran Inc Stock Price, News & Analysis

Bioxytran, Inc. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will discuss the company's participation in the Emerging Growth Conference on January 25, 2023, at 10:50 am EST. The conference will feature presentations by public companies across various growth sectors, focusing on innovative products and long-term growth potential. Investors are encouraged to preregister for attendance, and an archived webcast will be available post-event. Bioxytran is a clinical-stage biotechnology firm developing therapies for COVID-19 and other diseases, with its lead candidate being Prolectin-M, aimed at treating significant unmet medical needs.

BIOXYTRAN, INC. (OTCQB: BIXT) announced positive outcomes from its Phase 2 clinical trial for ProLectin-M, a treatment for COVID-19. The trial achieved a 100% response rate by day 7 in 34 patients, significantly outperforming the placebo (6%). Additionally, the company received an IND letter from India's CDSCO to optimize dosage for a planned 408 patient Phase III trial. An Indian subsidiary has been established to commercialize ProLectin-M upon approval, utilizing an FDA-approved manufacturing plant aimed at the 1.4 billion population in India.

BIOXYTRAN, INC. (OTCQB: BIXT) announces the establishment of its Indian subsidiary, Pharmalectin India Private Limited, aimed at launching ProLectin-M upon receiving CDSCO approval. The FDA-approved facility is positioned to cater to India's vast market of 1.4 billion. Currently, the company has not secured a distributor for its products. ProLectin-M, Bioxytran's leading drug candidate, targets viral diseases and shows promise in treating unmet medical needs. Further details can be found on their website.

BIOXYTRAN, INC. (OTCQB: BIXT) announced that its CMO, Michael Sheikh, will present the latest clinical trial results at the Emerging Growth Conference on December 14, 2022, from 1:45pm to 2:45pm EST. The conference aims to showcase public companies like Bioxytran, which is developing oral and intravenous therapies for COVID-19 and other viral diseases. Interested investors are encouraged to preregister to attend the conference and access updates. Archived webcasts will also be available for those unable to attend live.

Bioxytran, Inc. (BIXT) has received Investigational New Drug (IND) authorization from India's Central Drugs Standard Control Organization (CDSCO) to optimize dosage in COVID-19 patients. This approval paves the way for a future Phase III trial involving 408 patients, aimed at refining treatment strategies for COVID-19 and other viral diseases. Bioxytran focuses on developing oral and intravenous drugs targeting significant unmet medical needs, particularly with their leading drug candidate, ProLectin-M.

BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotech firm, has announced that Avise Analytics has reinitiated coverage of its stock, setting a fair valuation at $2.71 per share. The report highlights Bioxytran's ProLectin-M, which shows promising recovery rates for Covid-19 patients and targets a multi-billion-dollar market. Additionally, the company is advancing BXT-25 for stroke treatment, addressing the critical treatment window challenge. Despite positive developments, funding limitations could impact drug development timelines. More details can be found in the full report.

Bioxytran, Inc. (OTCQB: BIXT) announced positive results from its Phase 2 clinical trial involving a Galectin Antagonist for treating COVID-19. The study showed complete elimination of viral load in 100% of patients by day 7, compared to only 6% in the placebo group (p=.001). Additionally, 88% reached this result by day 3. There were no serious adverse events, and no viral rebounds were observed within 14 days. The trial supports plans for a Phase 2/3 registrational study and showcases the drug's novel mechanism of action against viral entry.

Bioxytran announced that its Scientific Advisor, Prof. Avraham Mayevsky, published a book titled Cortical Spreading Depression of Leão: From Mitochondrial Function to Brain Metabolic Score. This work is linked to Bioxytran’s Hypoxia platform technology, which utilizes the MDX Viewer for measuring tissue oxygenation. The technology aims to enhance drug development by providing real-time data on oxygen consumption in tissues, potentially revolutionizing clinical trials. Bioxytran is focusing on its leading drug, ProLectin-M, targeting unmet medical needs in virology and hypoxia.

Bioxytran, a clinical stage biotechnology company, announced a peer-reviewed article supporting its oral antiviral drug, ProLectin-M, published in the International Journal of Health Sciences. The article outlines the drug's mechanism of action (MOA) as a galectin-3 antagonist, confirming initial clinical data showing viral load reduction to undetectable levels in COVID-19 patients. ProLectin-M targets the SARS-CoV-2 virus and demonstrates promising preclinical results with non-toxic levels in humans. Bioxytran aims to address significant unmet medical needs in virology.